Wells Fargo analyst Vik Chopra has maintained their bullish stance on GMED stock, giving a Buy rating today.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Vik Chopra has given his Buy rating due to a combination of factors surrounding Globus Medical’s strategic acquisition of Nevro. This acquisition is expected to significantly enhance GMED’s market position by leveraging Nevro’s Spinal Cord Stimulation (SCS) technology and integrating it with GMED’s existing capabilities. The deal, set to be accretive to earnings by the second half of 2026, offers substantial potential for growth despite initial dilution in 2025 and 2026.
Moreover, GMED’s management has a clear plan to convert existing surgeons using competitive SCS technologies to Nevro’s solutions, maintaining the sales team to ensure continuity and incentivizing growth. With projected revenue growth and the expectation of achieving cost synergies, the company is well-positioned to improve operational efficiency. These strategic moves, coupled with maintaining robust revenue and EPS guidance for 2025, underpin Chopra’s optimistic outlook on Globus Medical’s stock.
According to TipRanks, Chopra is a 4-star analyst with an average return of 13.6% and a 64.15% success rate. Chopra covers the Healthcare sector, focusing on stocks such as NeuroPace, Masimo, and Globus Medical.
In another report released today, Barclays also maintained a Buy rating on the stock with a $100.00 price target.